A recent study suggests that weight‑loss medication using GLP‑1 receptors may improve certain social and economic outcomes for women.
The research, conducted independently by a professor of economics, analyzed data from a national panel survey. It compared women who had begun GLP‑1 therapy for weight loss with those who intended to start but had not yet done so.
Participants were evaluated on body mass, health, income, employment, partnership status, and overall well‑being before treatment. The study focused on women because they are more likely to use GLP‑1 drugs for weight control, and it excluded individuals taking the medication for diabetes.
Findings show that women who successfully lost weight experienced notable changes: marriage or cohabitation among single women rose 29% after roughly 18 months, and job prospects for those initially unemployed increased 27% over the same period. Women already employed did not show significant career advancement.
Experts attribute these shifts to reduced societal bias in new relationships and job interviews. Confidence and visibility improvements after weight loss may enhance interview performance and networking opportunities.
A plastic surgeon observed that many patients seek body contouring procedures following significant GLP‑1 weight loss, noting a visible boost in confidence. However, the study did not find improvements in depression, loneliness, or overall life satisfaction despite the rise in marriage and employment rates.
The research is observational, not a randomized trial, so it demonstrates only an association, not causation. Additional limitations include its focus on women alone, reliance on self‑reported data, and lack of information on changes in earnings for new jobs.
While GLP‑1 users appear to achieve better external outcomes, the absence of reported gains in overall well‑being raises questions about the real impact of these changes on quality of life.
